cis-2-acetyl-3-(2',3'-dichlorophenyl)prop-2-enoic acid | 1346550-31-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: cis-2-acetyl-3-(2',3'-dichlorophenyl)prop-2-enoic acid
• 英文别名: (2Z)-2-[(2,3-dichlorophenyl)methylidene]-3-oxobutanoic acid
• CAS: 1346550-31-9
• 化学式: C₁₁H₈Cl₂O₃
• 分子量: 259.089
• InChiKey: DPGZVVIFALBCPD-YVMONPNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  cis-2-acetyl-3-(2',3'-dichlorophenyl)prop-2-enoic acid 、 丁酸氯甲酯 在 丁酸氯甲酯 作用下， 生成 cis-2-(2',3'-dichloro-benzylidene)-3-oxo-butyric acid butyryloxymethyl ester
  参考文献：
  名称：

  [EN] PROCESS FOR PREPARATION OF CLEVIDIPINE AND ITS INTERMEDIATE
  [FR] PROCÉDÉ DE PRÉPARATION DE CLÉVIDIPINE ET D'UN PRODUIT INTERMÉDIAIRE ASSOCIÉ

  摘要：

  本发明涉及一种从t-丁基甲基4-(2',3'-二氯苯基)-2,6-二甲基-1,4-二氢吡啶-3,5-二羧酸酯中去除t-丁基基团的方法，从而得到1,4-二氢-2,6-二甲基-4-(2',3'-二氯苯基)-5-甲氧羰基-3-吡啶羧酸，进一步转化为具有高效液相色谱纯度超过99%的克列维地平。

  公开号：

  WO2012069989A1
• 作为产物：
  描述：

  tert-butyl (2Z)-2-[(2,3-dichlorophenyl)methylidene]-3-oxobutanoate 以80的产率得到cis-2-acetyl-3-(2',3'-dichlorophenyl)prop-2-enoic acid
  参考文献：
  名称：

  [EN] PROCESS FOR PREPARATION OF CLEVIDIPINE AND ITS INTERMEDIATE
  [FR] PROCÉDÉ DE PRÉPARATION DE CLÉVIDIPINE ET D'UN PRODUIT INTERMÉDIAIRE ASSOCIÉ

  摘要：

  本发明涉及一种从t-丁基甲基4-(2',3'-二氯苯基)-2,6-二甲基-1,4-二氢吡啶-3,5-二羧酸酯中去除t-丁基基团的方法，从而得到1,4-二氢-2,6-二甲基-4-(2',3'-二氯苯基)-5-甲氧羰基-3-吡啶羧酸，进一步转化为具有高效液相色谱纯度超过99%的克列维地平。

  公开号：

  WO2012069989A1

文献信息

• DRUG DERIVATIVES
  申请人：Craighead Mark

  公开号：US20130225594A1

  公开（公告）日：2013-08-29

  The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.

  本发明涉及已知活性药物化合物的衍生物。这些衍生物通过是活性化合物的氧化还原衍生物与母体活性化合物相区别。这意味着活性化合物中的一个或多个官能团已转化为另一组，在一项或多项反应中，这可以被认为代表氧化态的变化。我们通常将这些化合物称为氧化还原衍生物。发明中的衍生物可能与原始母体活性药物化合物仅通过单一步骤转换有关，或者可能通过包括一个或多个氧化态变化的几个合成步骤与之相关。在某些情况下，经过两个或更多转换后获得的官能团可能与母体活性化合物处于相同的氧化态（我们将这些化合物包括在我们的氧化还原衍生物定义中）。在其他情况下，发明的衍生物的氧化态可以被认为是与母体化合物不同的。在许多情况下，发明中的化合物本身就具有固有的治疗活性。在某些情况下，相对于母体化合物的相同靶点或靶点，这种活性与母体化合物针对该靶点或靶点的活性一样好或更好。
• PREPARATION OF DIHYDROPYRIDINES
  申请人：VISHNU NEWADKAR RAVINDRANATH

  公开号：US20110275825A1

  公开（公告）日：2011-11-10

  The invention relates to a method and compounds for the preparation of clevidipine butyrate, a very short acting hypertensive calcium antagonist, as well as the synthesis of these compounds useful for the preparation of clevidipine (also known as clevidipine butyrate). Moreover the invention also discloses polymorphic forms of clevidipine butyrate, useful for the preparation of pharmaceutical compositions, and processes to prepare them.

  该发明涉及一种用于制备克莱维地平丁酸酯的方法和化合物，克莱维地平丁酸酯是一种作用时间非常短的高血压钙拮抗剂，以及用于制备克莱维地平（也称为克莱维地平丁酸酯）的这些化合物的合成。此外，该发明还揭示了克莱维地平丁酸酯的多态形式，用于制备药物组合物，并揭示了用于制备这些多态形式的方法。
• Ameliorant of cerebral circulation and optical isomer of nb-818, processes for its production and its use
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0311053A2

  公开（公告）日：1989-04-12

  An ameliorant of cerebral circulation which contains 2-carbamoyloxymethyl-4-(2,3-dichlorophenyl)-6-methyl-1,4-­dihydropyridine-3,5-dicarboxylic acid 3-isopropyl ester 5-methyl ester as an active ingredient.

  一种改善脑循环的改良剂，其中包含2-氨基甲酸氧甲基-4-(2,3-二氯苯基)-6-甲基-1,4-二氢吡啶-3,5-二羧酸3-异丙酯5-甲酯作为活性成分。
• [EN] PROCESS FOR PREPARATION OF CLEVIDIPINE AND ITS INTERMEDIATE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE CLÉVIDIPINE ET D'UN PRODUIT INTERMÉDIAIRE ASSOCIÉ
  申请人：CADILA PHARMACEUTICALS LTD

  公开号：WO2012069989A1

  公开（公告）日：2012-05-31

  The present invention relates to a process for the removal of t-butyl group from t-butyl methyl 4-(2',3'-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate to provide-1,4-dihydro-2,6-dimethyl-4-(2',3'-dichorophenyl)-5-methoxycarbonyl-3-pyridine- carboxylic acid, which is further converted to to yield clevidipine having HPLC purity over 6 99%.

  本发明涉及一种从t-丁基甲基4-(2',3'-二氯苯基)-2,6-二甲基-1,4-二氢吡啶-3,5-二羧酸酯中去除t-丁基基团的方法，从而得到1,4-二氢-2,6-二甲基-4-(2',3'-二氯苯基)-5-甲氧羰基-3-吡啶羧酸，进一步转化为具有高效液相色谱纯度超过99%的克列维地平。
• CRYSTALLINE POLYMORPHS OF CLEVIDIPINE BUTYRATE
  申请人：Laboratorios Lesvi, S.L.

  公开号：EP3020704A2

  公开（公告）日：2016-05-18

  The invention relates to a novel method and novel compounds for the preparation of clevidipine butyrate, a very short acting hypertensive calcium antagonist, as well as the synthesis of these new compounds useful for the preparation of clevidipine (also known as clevidipine butyrate). Moreover the invention also discloses new polymorphic forms of clevidipine butyrate, useful for the preparation of pharmaceutical compositions, and processes to prepare them.

  本发明涉及一种新的方法和新的化合物，用于制备克列维地平丁酯，一种非常短效的高血压钙拮抗剂，以及合成这些新化合物，用于制备克列维地平（也称克列维地平丁酯）。此外，本发明还揭示了克列维地平丁酯的新的多形态形式，有用于制备药物组成物的，以及制备它们的过程。